Amyloid imaging by small animal PET (µPET) in models of Alzheimer's disease (AD) offers the possibility to track amyloidogenesis and brain energy metabolism.
F-GE180
for imaging activated microglia (18kD translocator protein ligand, TSPO), and static 30-60 min recordings with 18 F-FDG for energy metabolism and 
Results:
SUVR at 60-90 min p.i. gave robust quantitation of 18 F-GE180, which correlated well with DVR calculated from the entire recording, and using a white matter reference region. Relative to age-matched WT, 18 F-GE180 SUVR was slightly elevated in PS2APP mice at five months (+9%; p<0.01), and distinctly increased
INTRODUCTION
Alzheimer's disease (AD) is the most common cause of dementia, with its exponentially increasing incidence as a function of age among the elderly, it is imposing an ever more onerous burden on health care (1) . This state of affairs motivates a worldwide effort to find new biomarkers predicting future cognitive decline in patients with suspicious of early AD, and likewise for use as outcome measures in clinical trials of innovative disease-modifying agents (2) .
Immunologically-mediated neuroinflammation is implicated in the pathophysiological processes of AD (3, 4) , which are classically characterized by accumulation of extracellular β-amyloid plaques and intracellular neurofibrillary tangles (5) . Many aspects of the classical β-amyloid pathology are emulated in various transgenic rodent models for AD (6, 7) ; and translational studies of these processes are facilitated by small animal positron-emission-tomography (µPET) using radioligands for imaging of AD biomarkers in these rodent models (8) . In particular, μPET imaging of β-amyloid has been successfully established in the past few years (9, 10) . However, information regarding neuroinflammation in these models remains sparse and rather inconsistent (11) (12) (13) .
Neuroinflammation can be assessed by molecular imaging with several 11 C labelled radiotracers targeting the 18kD translocator protein (TSPO), which is highly expressed at the outer mitrochondrial membrane of activated microglia (14, 15) ; the brief physical half-life of Carbon-11 presents logistic difficulties for its widespread use. However, novel 18 F-fluorinated second-generation TSPO radiotracers now offer a more practical means to undertake imaging also at sites lacking a cyclotron/radiochemistry facility. Among the various such compounds, 18 F-GE180 has emerged as a TSPO ligand affording excellent signal-to-noise ratio and brain kinetics favourable for the detection of microglia activation (16, 17) . However, monitoring of neuroinflammation in AD mice by this agent remains to be established. F-florbetaben was performed as previously described (10) . This procedure yielded a radiochemical purity exceeding 98%, and a specific activity of 80±20 GBq/µmol at end of synthesis.
18
F-FDG was purchased commercially.
Animals
All experiments were carried out in compliance with the National Guidelines for Animal Protection, Germany and the approval of the regional animal care committee (Regierung Oberbayern), and were overseen by a veterinarian.
Animals were housed in a temperature-and humidity-controlled environment with a 12-h light-dark cycle, with free access to food (Ssniff, Soest, Germany) and water.
The transgenic B6.PS2APP (line B6.152H) is homozygous for the human presenilin (PS) 2, N141I mutation and also the human amyloid precursor protein (APP) K670N, M671L mutation. The APP and PS2 transgenes are driven by mouse Thy-1 and mouse prion promoters, respectively. This line had been created by co-injection of both transgenes into C57Bl/6 zygotes (19).
Homozygous B6.PS2APP (PS2APP) mice show first appearance of plaques in the cortex and hippocampus at five to six months of age (20) .
Study Overview
The study design consisted of a pilot study and the main study.
In the pilot study, autoradiography ex vivo and in vitro was performed with 18 F-GE180, followed by immunohistochemistry in small groups of WT and TG mice at 10 and 22 months of age.
In the main study, µPET scans were obtained with the three 
µPET Data Analyses
Volumes-of interest (VOIs) were defined on the MRI mouse atlas ( 
Ex Vivo and In Vitro Autoradiography
In the pilot study, autoradiography experiments were carried out to confirm the specificity of 
Immunohistochemistry: Acquisition and Image Analysis
Plaque and microglia load were calculated as the summed area of all labelled plaques and microglia, and reported as percentage densities relative to the entire cerebral cortex areas. These analyses were performed by an operator who was blind to the μPET results. Methodological details can be found in Supplementary
Methods.
Statistics
Group comparisons of VOI-based µPET results between WT and TG mouse groups were assessed by one-way analysis of variance (ANOVA) and Tukey 
RESULTS

Validation of 18 F-GE180 PET
VOI based analyses were performed with the dynamic dataset in order to establish the kinetics of quantification, the use of SUVR in a static frame recorded in the interval 60-90 min p.i. provides a convenient surrogate maker for specific binding (Fig. 2B ).
In this regard there was excellent linear relationship between DVR, calculated for the entire 90 minute recording, and the 60-90 min static frame SUVR (R=0.99, p<0.001) (Fig. 2C) . Test-retest analyses confirmed as well the robustness of 60-90 min SUVRFBR/WM for the forebrain target region in TG animals (best fit:
R=0.98, linear, p<0.001; test-retest variability 1.9%).
Variance in the forebrain 
Triple Tracer µPET analyses
All µPET results are provided in F-florbetaben SUVRFBR/CBL were observed. The age dependence in the uptake of the three tracers is presented in Fig. 5 .
Autoradiography and Immunohistochemistry
IBA-1 antibody in vitro quantitation (occupancy(%)) in the whole group of PS2APP mice showed strong positive correlation with the 18 F-GE180 uptake in vivo (R=0.61; p<0.005).
F-florbetaben uptake and percentage plaque load (%)
as assessed by methoxy-X04 histology had an very high correlation finding (R=0.80; p<0.001), as in our previous β-amyloid-PET studies (10, 18) . Both immunohistochemical staining methods indicated a progression of pathophysiology with age in a manner congruent with the PET data (Supplemental Fig. 2 ).
The pattern of 18 F-GE180 binding seen by autoradiography ex vivo resembled the binding observed in the µPET scan, and triple labelling in vitro showed co-localization of TSPO activation with fibrillar β-amyloid deposits (Fig. 6) .
Qualitatively, the 18 F-GE180 autoradiography in vitro was more diffuse than for 18 F-florbetaben, which showed a more focal pattern. Prior incubation of brain sections with TSPO antibody completely blocked 18 F-GE180 labelling in the forebrain, thus indicating the specific association of increased TSPO expression and amyloid plaques (Supplemental Fig. 3 ).
DISCUSSION
We present the first small animal PET study with three different 
F-GE180 reference region
One key issue in detecting microglial activation by PET is the lack of an appropriate pathology-free reference tissue, i.e. a region devoid of TSPO expression in mouse brain (23) . In the absence of a "true" reference region, a recent PET study of TSPO expression in AD patients showed clear benefits for a SUVR analysis with the cerebellum as a pseudo-reference region, compared to quantitation relative to arterial blood input for 11 C-PBR28 (24) . Therefore, we tested several reference tissues for our novel ligand for TSPO, 18 F-GE180. Our analyses revealed that a reference region composed of white matter voxels in brainstem and cerebellum delivered comparable SUV results between TG and WT groups at different ages. In contrast the whole brain and, to a lesser degree, the cerebellum showed elevated SUV in TG mice with marked pathology, thus being less suitable as a reference region. The white matter reference VOI was of a size (29mm³) sufficient to minimize signal loss to due to partial volume effects (25) . Furthermore, the SUVR approach distinctly minimized the intragroup variance in TSPO results compared to that with simple SUV calculation, which is in line with findings from the human study cited above (24) . Thus we see a clear advantage for a cerebral pseudo-reference region in the semi-quantitative analysis of preclinical TSPO imaging. 
F-GE180 time window
In vivo therapy monitoring
In our hands, microglial activation and amyloid levels as assessed by µPET had high inter-animal variability as has been reported for other AD mouse models 
